Neural Tube Defects — Influence of "Espresso" on Adsorption of Myo-inositol
Citation(s)
Cavalli P, Copp AJ Inositol and folate resistant neural tube defects. J Med Genet. 2002 Feb;39(2):E5. doi: 10.1136/jmg.39.2.e5. No abstract available.
Cavalli P, Tedoldi S, Riboli B Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs. Birth Defects Res A Clin Mol Teratol. 2008 Jul;82(7):540-2. doi: 10.1002/bdra.20454. No abstract available.
De Castro SC, Leung KY, Savery D, Burren K, Rozen R, Copp AJ, Greene ND Neural tube defects induced by folate deficiency in mutant curly tail (Grhl3) embryos are associated with alteration in folate one-carbon metabolism but are unlikely to result from diminished methylation. Birth Defects Res A Clin Mol Teratol. 2010 Aug;88(8):612-8. doi: 10.1002/bdra.20690.
Lorenzo AM, Leon D, Castillo CA, Ruiz MA, Albasanz JL, Martin M Maternal caffeine intake during gestation and lactation down-regulates adenosine A1 receptor in rat brain from mothers and neonates. J Neurosci Res. 2010 May 1;88(6):1252-61. doi: 10.1002/jnr.22287.
van Straaten HW, Copp AJ Curly tail: a 50-year history of the mouse spina bifida model. Anat Embryol (Berl). 2001 Apr;203(4):225-37. doi: 10.1007/s004290100169.
Influence of "Espresso" on Adsorption of Orally Administrated Myo-inositol in Humans
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
